Abdominal aortic aneurysm pathology and progress towards a medical therapy
Moxon, Joseph V., Krishna, Smriti M., Singh, Tejas P., and Golledge, Jonathan (2020) Abdominal aortic aneurysm pathology and progress towards a medical therapy. In: Fitridge, Robert, (ed.) Mechanisms of Vascular Disease: a textbook for vascular specialists. Springer, Cham, Switzerland, pp. 263-291.
|
PDF (Accepted Author Version)
- Accepted Version
Download (816kB) | Preview |
Abstract
Abdominal aortic aneurysm (AAA) is an important cause of mortality in older adults due to aortic rupture. Surgical repair (either by endovascular or open surgery) is the only treatment for AAA. However, large randomized controlled trials have demonstrated that elective repair of small (<55 mm) AAAs does not reduce all-cause mortality. Most AAAs detected through screening programs or incidental imaging are too small to warrant immediate surgical repair. Such patients are managed conservatively with repeated imaging to monitor AAA diameter. Nonetheless, 60–70% of AAAs managed in this way eventually grow to a size warranting elective surgery. Discovery of a drug therapy which effectively slows the growth of small AAAs has significant potential to improve patient welfare and reduce the number of individuals requiring elective surgery. This chapter reviews the current understanding of AAA pathogenesis gained through assessment of animal models and clinical samples. Previous AAA drug trials are also discussed. Finally, the challenges in developing AAA drugs are outlined.
Item ID: | 60619 |
---|---|
Item Type: | Book Chapter (Research - B1) |
ISBN: | 3-030-43683-7 |
Keywords: | Aortic aneurysm, Matrix metalloproteinases, Biomarkers, Clinical trials, Extracellular matrix, Aneurysm growth |
Copyright Information: | Pubished Version: © Springer Nature Switzerland AG 2020. Accepted version: Authors whose work is accepted for publication in a non-open access Springer book may deposit their authors' accepted manuscript (AAM) in their institutional or funder repository, provided that the following conditions are observed: 24 months embargo. |
Date Deposited: | 09 Dec 2020 01:33 |
FoR Codes: | 32 BIOMEDICAL AND CLINICAL SCIENCES > 3201 Cardiovascular medicine and haematology > 320101 Cardiology (incl. cardiovascular diseases) @ 100% |
SEO Codes: | 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920103 Cardiovascular System and Diseases @ 100% |
Downloads: |
Total: 122 Last 12 Months: 8 |
More Statistics |